GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » Earnings Yield (Joel Greenblatt) %

Autolus Therapeutics (Autolus Therapeutics) Earnings Yield (Joel Greenblatt) % : -17.48% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics Earnings Yield (Joel Greenblatt) %?

Autolus Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $934.61 Mil. Autolus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-163.34 Mil. Autolus Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -17.48%.

The historical rank and industry rank for Autolus Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

AUTL' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21100.07   Med: -46.16   Max: 71908.48
Current: -18.69

During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Autolus Therapeutics was 71908.48%. The lowest was -21100.07%. And the median was -46.16%.

AUTL's Earnings Yield (Joel Greenblatt) % is ranked worse than
54.19% of 1408 companies
in the Biotechnology industry
Industry Median: -14.54 vs AUTL: -18.69

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Autolus Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Autolus Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Autolus Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics Earnings Yield (Joel Greenblatt) % Chart

Autolus Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial -34.01 -45.05 -77.52 476.19 -17.48

Autolus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 476.19 -5,000.00 -85.47 -65.79 -17.48

Competitive Comparison of Autolus Therapeutics's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Autolus Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Autolus Therapeutics's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.



Autolus Therapeutics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Autolus Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-163.335/934.61144
=-17.48 %

Autolus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-163.34 Mil.



Autolus Therapeutics  (NAS:AUTL) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Autolus Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Autolus Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Autolus Therapeutics (Autolus Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.